( g blood vessels NFkB decoy which contr...)Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan,Health

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the potential approval of AnGes' HGF product candidate, as well as Vical's focus, collaborative partners, and product candidates. Risks and uncertainties include whether AnGes will file for marketing approval in Japan; whether the HGF product candidate will be approved in Japan; whether the market for the HGF product will be significant; whether any product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any other product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contacts:  Investors:                         Media:

               Alan R. Engbring                   Susan Neath

               Vical Incorporated                 Porter Novelli Life Sciences

               (858) 646-1127                     (619) 849-6007

               Website:  www.vical.com

CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007

Web site
'"/>